EQS-News: DEFENCE’S SUCCESSFUL SUBMISSION OF AN INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR ACCUTOX® AS AN INJECTABLE ANTICANCER TREATMENT FOR SOLID TUMORS
AccuTOX® is a derivative of the initial Accum® molecule, which has been reported to target cancer on multiple fronts.
- AccuTOX® is a derivative of the initial Accum® molecule, which has been reported to target cancer on multiple fronts.
- In addition, the application describes the manufacture of the drug substance and drug product to be used in human clinical trials.
- “We are thrilled and excited that Defence has achieved a successful submission on its first IND, which represents an important milestone towards advancing AccuTOX® into the clinic.
- Several other secondary parameters including therapeutic efficacy will be monitored in treated patients in preparation for a Phase IIa trial on a basket of tumors.